Making medicines affordable for everyone across America

Our Call to Action

Leading biopharma Innovators, investors, and patient groups urged congress to solve affordability for patients through insurance reform. More than 300 industry leaders share ideas on how to save all Americans money while preserving research and development. Caution that government price controls will cease biopharma investment and significantly reduce availability of new medicines. Read what more here.

Do more for patients, preserve innovation.

1000+ Investors, researchers, patients, & innovators urge critical fixes to Senate Rx Bill

A few tweaks can meaningfully improve patient Rx affordability and preserve biopharma innovation. The letter shares compromises on how Congress can lower Medicare Rx deductibles, give the government greater power to set prices, and make sure biopharma research and development remains vigorous for both drugs and biologics.
You can read and join our letter here.
Read investor analysis here.
Learn what this bill will mean for future cures.
High health plan copays are harming American families. Even with “insurance," one in four cannot afford them. If a doctor prescribes a treatment and the insurer authorizes it, the copay should be affordable. What are premiums for anyway?

Watch what Abbie is saving for here.
Our Videos & Animation
Explore NPLB's core principles, positions and plans to make medicines affordable for all Americans, encourage innovation, and ensure that patients are heard.

What we're tweeting (and retweeting)

Follow us @NPLB_org
Follow us @NPLB_org

What we're tweeting (and retweeting)

Our goals

Make sure that everyone in America has affordable healthcare they can actually use and guarantee that our country continues to invest in new medicines that will help patients now and in the future.

out-of-pocket costs

Expand insurance
to everyone

Ensure that all drugs go generic

All posts

Misguided Rating Cancels Rare Disease Patients

Flawed math harms patients and society.

One Thousand Investors, Researchers, Patients, & Innovators Sign Letter Urging Critical Fixes to Senate Rx Bill

NPLB released a coalition letter urging fixes to the Senate Reconciliation Drug bill.

Biopharma industry mobilizing support for Ukraine

How you can help Ukraine, a well-researched plan: Direct Relief

“Abbie” Video Highlights Need for Insurance Reforms that Lower Out-of-Pocket Costs

If a doctor prescribes a treatment and the insurer authorizes it, the copay should be affordable.

Op-ed: Fix BBB’s Rx Provisions so Patients Aren’t Stuck With High Bills and More Needles

Congress can achieve Rx affordability and innovation with achievable BBB modifications

KOLs call for updated Build Back Better to level playing field

Call for same timeline for biologics, small molecules, and lower out-of-pocket costs.

We're determined to help you get the care and medicines your doctors say you need.

We are dedicated to creating and maintaining patient access to affordable drugs by holding both insurance and pharmaceutical companies accountable for their policies and practices.

About us
All articles
Affordability and Innovation

We are championing new laws to get insurance companies to do away with copays and out-of-pocket expenses.

We are pushing for reforms to guarantee that drug companies let their drugs go generic when they're supposed to do so.

Who we are

Explore our cause

Help for patients

Don’t despair. There’s help for you: assistance with copays, deductibles and other expenses.

Our strategy

Coalition building. Raising awareness. Encouraging innovation. Changing perceptions and policy. Making medicines affordable.

Our presentations

Clear-cut ideas and solutions. The science, economics and policy of affordability and innovation.

Did you know?

Increasing out-of-pocket costs by just $10 per prescription causes a 33% rise in mortality because fewer patients take the drugs their doctors prescribe.

Source: National Bureau of Economic Research, involved